Researchers from National Taiwan University developed PanMETAI, an AI-powered diagnostic platform that detects early-stage pancreatic cancer using a small blood sample. The system combines AI with NMR metabolomics to analyze metabolic fingerprints in the blood.
In testing, the platform achieved up to 94% diagnostic accuracy and showed strong performance across international patient groups. By analyzing metabolic signals alongside biomarkers like CA19-9 and Activin A, the model can identify subtle metabolic changes linked to early cancer.